Background: Multiple published quantitative systematic reviews have reported on adverse
events associated with the use of sodium glucose co-transporter 2 (SGLT-2) inhibitors in …

Aims To summarize reported cancer events associated with SGLT‐2 inhibitors used in
patients with type 2 diabetes mellitus, as well as assess the quality of included reviews …

Background Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are a novel class of
pharmacotherapeutics for type 2 diabetes management that work by reducing renal …

Objective Evidence of an increased dementia risk with insulin use in type 2 diabetes is
weakened by confounding by indication and disease severity. Herein we reassess this …

OBJECTIVE Severe hypoglycemia is associated with an increased risk of dementia. We
examined if the association is consistently present in mid-and late-life hypoglycemia …

Aims To assess post‐initiation predictors of discontinuation of sodium‐glucose cotransporter‐
2 (SGLT2) inhibitors compared to dipeptidyl‐peptidase‐4 (DPP‐4) inhibitors in the United …

Aims Disproportionality analysis is a common pharmacovigilance tool to detect safety
signals of type 2 diabetes medications from spontaneous drug reporting databases. The aim …

Introduction An increased risk of myopathy due to a potential interaction between sodium
glucose co-transporter-2 inhibitors (SGLT-2i) and HMG-CoA reductase inhibitors (statins) …

Background Previous studies have shown hypoglycaemia to be associated with an
increased risk of dementia; however, there are several design challenges to consider. The …

Objectives To examine the associations between COVID-19 pandemic waves (1–4) and
prevalent antipsychotic, antidepressant, benzodiazepine, anticonvulsant, and opioid use …